Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B
Sponsor: Golden Biotechnology Corporation
Summary
Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.
Official title: A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B
Key Details
Gender
All
Age Range
20 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2018-02-12
Completion Date
2023-06-16
Last Updated
2026-10-19
Healthy Volunteers
No
Conditions
Interventions
Antroquinonol
Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.
placebo
The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects
Locations (1)
Chung Shan Medical University Hospital
Taichung, Taiwan, Taiwan